Cost-effectiveness of lung transplantation in the Netherlands - A scenario analysis

被引:40
作者
Al, MJ
Koopmanschap, MA
van Enckevort, PJ
Geertsma, A
van der Bij, W
de Boer, WJ
TenVergert, EM
机构
[1] Erasmus Univ, Inst Med Technol Assessment, NL-3000 DR Rotterdam, Netherlands
[2] Univ Groningen Hosp, Off Med Technol Assessment, Groningen, Netherlands
[3] Univ Groningen Hosp, Dept Pulm Dis, Groningen, Netherlands
[4] Univ Groningen Hosp, Dept Cardiothorac Surg, Groningen, Netherlands
关键词
cost-effectiveness; cost utility; lung transplantation; microsimulation; scenario-analysis;
D O I
10.1378/chest.113.1.124
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: To calculate cost-effectiveness of scenarios concerning lung transplantation in the Netherlands. Design: Microsimulation model predicting survival, quality of life, and costs with and without transplantation program, based on data of the Dutch lung transplantation program of 1990 to 1995. Setting: Netherlands, University Hospital Groningen. Patients: Included were 425 patients referred for lung transplantation, of whom 57 underwent transplantation. Intervention: Lung transplantation. Results: For the baseline scenario, the costs per life-year gained are G 194,000 (G=Netherlands guilders) and the costs per quality-adjusted life-year (QALY) gained are G 167,000. Restricting patient inflow ("policy scenario") lowers the costs per life-year gained: G 172,000 (costs per QALY gained: G 144,000). The supply of more donor lungs could reduce the costs per life-year gained to G 159,000 (G 135,000 per QALY gained; G1=US$0.6, based on exchange rate at the time of the study). Conclusions: Lung transplantation is an expensive but effective intervention: survival and quality of life improve substantially after transplantation, The costs per life-year gained are relatively high, compared with other interventions and other types of transplantation. Restricting the patient inflow and/or raising donor supply improves cast-effectiveness to some degree. Limiting the extent of inpatient screening or lower future costs of immunosuppressives may slightly improve the cost-effectiveness of the program.
引用
收藏
页码:124 / 130
页数:7
相关论文
共 13 条
[1]  
BJORK S, 1992, EUROQOL C P, P2
[2]  
DEBOER WJ, BEHANDELINGSPROTOCOL
[3]  
Duan N., 1983, J EC BUSINESS STATIS, V1, P115, DOI [DOI 10.1080/07350015.1983.10509330, DOI 10.2307/1391852]
[4]  
HOSENPUD JD, 1995, J HEART LUNG TRANSPL, V14, P805
[5]  
MICHEL BC, 1992, LEVERTRANSPLANTATIE
[6]  
RAMSEY SD, 1995, J HEART LUNG TRANSPL, V14, P870
[7]   THE COST-EFFECTIVENESS OF LUNG TRANSPLANTATION - A PILOT-STUDY [J].
RAMSEY, SD ;
PATRICK, DL ;
ALBERT, RK ;
LARSON, EB ;
WOOD, DE ;
RAGHU, G .
CHEST, 1995, 108 (06) :1594-1601
[8]  
TENVERGERT EM, IN PRESS CHEST
[9]  
TENVERGERT EM, IN PRESS EUR RESP J
[10]  
VanEnckevort PJ, 1997, HEALTH ECON, V6, P479, DOI 10.1002/(SICI)1099-1050(199709)6:5<479::AID-HEC287>3.0.CO